Tag: AstraZeneca

April 21, 2022 Off

AstraZeneca’s Evusheld Reduces the Risk of COVID-19 by 77%

By Author

AstraZeneca has announced detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that  Evusheld (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and by 83% in the six month follow-up analysis, compared to placebo.

March 28, 2022 Off

AstraZeneca’s Evusheld Approved in the EU for Prevention of COVID-19

By Dino Mustafić

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

March 16, 2022 Off

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer

By Dino Mustafić

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.